Here at PharmaTell, we have Eyes on FDA Approvals for 2025. Below, we share the monthly Novel Drug and Biologic License Application Approval

We've had Eye's On the JP Morgan Healthcare Conference, Lifesciences 2024 restructuring stats, and some new drug development partnerships.

According to an annual PwC study released in December, the amount of M&A activity in the pharmaceutical and life sciences sectors in 2024...

Check out the final listings of FDA NDA and BLA approvals for 2024.

We've highlighted a few firms: Lilly, AbbVie, Pfizer, Novo Nordisk, BMS, Roche, Novartis, Merck, AstraZeneca, GSK, Viatris, Teva, and Amgen.

This week, we had eyes on data readouts, launch metrics, M&A, and more. Catch up with the news from Roche, AstraZeneca, Lundbeck, and AbbVie